Hansa Biopharma

Hansa Biopharma announced that the 12‑month results of the US phase‑3 ConfIdeS study of imlifidase have been accepted for presentation at the American Transplant Congress in Boston on June 22, 2026. The presentation will cover the primary endpoint eGFR, key secondary endpoints and safety data and will be given by Dr. Robert Montgomery. Separately, the FDA accepted the regulatory filing for imlifidase in February 2026 and set a decision date of December 19, 2026. » More on de.investing.com

Hansa Biopharma reported a 37% drop in revenue for Q3 2025 to SEK 31m, leading to a roughly 12% fall in its share price. Idefirix sales fell 24%, operating loss widened to SEK 147.6m and gross margin climbed to 60%. Management points to positive phase‑3 data for Imlifidase and is preparing a potential FDA filing with possible market entry in 2026, but continues to see regulatory and market risks. » More on de.investing.com

Hansa Investment shareholders voted at the general meeting with an overwhelming majority (each over 97%) in favor of all resolutions required for the planned share-swap merger with Ocean Wilsons. The resolutions include a capital increase, a new investment policy, higher total remuneration for directors and buyback programmes. The court hearing to approve the scheme begins on 22 September 2025; subject to court approval, new Hansa shares are to be issued shortly thereafter and admitted to trading on the London Stock Exchange. The transaction remains subject to court approval and other conditions and has a long-stop date of 31 December 2025. » More on de.investing.com

Hansa Investment Company Limited and Ocean Wilsons Holdings Limited have agreed to a share exchange that will create an investment company with net assets exceeding £900 million. The new company will manage a diversified global portfolio, achieve cost savings through a new fee structure, and prioritize share buybacks over dividends. The transaction is subject to shareholder approval and is expected to be completed in September 2025. » More on de.investing.com

Hansa Biopharma increased product revenue by 76% in the second quarter of 2025 and achieved significant progress in its clinical pipeline, but missed overall revenue and earnings forecasts. The company stabilized its financial position through a capital increase and restructuring measures, yet continues to face operating losses and market uncertainties. Key clinical trial results are expected in the second half of the year, while acceptance of its main product, IDEFIRIX, continues to grow in Europe. » More on de.investing.com